Evidence map›Paper›PMID 38753106›Full record

ArticleAdvances in therapy2024

florio

Ester Zapotocka, Angelika Batorova, Ernest Bilic, Ana Boban, Carmen Escuriola Ettingshausen, Barbara Faganel Kotnik, Radomira Hrdlickova, Pawel Laguna, Jan Máchal, Laszlo Nemes and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ester ZapotockaDepartment of Pediatric Hematology/Oncology, University Hospital Motol, V Úvalu 84, 150 06, Prague, Czech Republic. ester.zapotocka@fnmotol.cz.
Angelika BatorovaDepartment of Hematology and Transfusion Medicine, National Hemophilia Center, Faculty of Medicine of Comenius University and University Hospital, Bratislava, Slovakia.
Ernest BilicDivision of Hematology and Oncology, Department of Pediatrics, University Hospital Center Zagreb, Zagreb, Croatia.
Ana BobanDivision of Hematology, Department of Internal Medicine, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia.
Carmen Escuriola EttingshausenHZRM Hamophilie Zentrum Rhein Main, Mörfelden-Walldorf, Germany.
Barbara Faganel KotnikDepartment of Hematology and Oncology, University Children's Hospital, University Medical Center Ljubljana, Ljubljana, Slovenia.
Radomira HrdlickovaBlood Center, University Hospital Ostrava, Ostrava, Czech Republic.
Pawel LagunaDepartment of Pediatric, Oncology, Hematology and Transplantology, Warsaw Medical University, Warsaw, Poland.
Jan MáchalDepartment of Pediatric Hematology and Biochemistry, Masaryk University, Brno, Czech Republic.
Laszlo NemesNational Hemophilia Centre and Haemostasis Department, Central Hospital of Northern Pest-Military Hospital, Budapest, Hungary.
Irena Preloznik ZupanDepartment of Hematology, University Medical Center Ljubljana, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Gediminas PurasSwedish Orphan Biovitrum AG, Basel, Switzerland.
Marianna ZomboriDepartment of Onco-Hematology, Heim Pál Nationale Institute of Pediatrics, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionflorio

methodsThis is a follow-up of a two-part user survey conducted in Central Europe. People with hemophilia and parents/caregivers of children with hemophilia using florio HAEMO and who completed part one were invited to complete a second online questionnaire at least 4 months later.

resultsFifty participants (83.3%) who completed part one of the survey continued to use the florio HAEMO app and completed part two. Of 14 participants who chose to use the app with a wearable, more than half (57.1%) were aged between 13 and 25 years. Overall, the results demonstrated that florio HAEMO is very easy or rather easy to use, especially for individuals pairing the app with a wearable. Most people using a wearable indicated that florio HAEMO was very or rather important in bringing certainty to daily activities (85.7%). Notably, 14 of 36 (38.9%) non-wearable users indicated that they would prefer to pair the app with a wearable in the future.

conclusionsAdherence to the florio HAEMO app is maintained over an extended period of use. Pairing the app with a wearable might enable easier access to app features, increase data entry motivation and provide more certainty about daily activities for people with hemophilia.

Indexed as

Hemophilia APatient PreferenceWearable Electronic DevicesAdolescentAdultChildEuropeFemaleHumansLongitudinal StudiesMaleMiddle AgedMobile ApplicationsPatient CompliancePatient SatisfactionSurveys and QuestionnairesAdherenceFlorio HAEMOHemophiliaPatient satisfactionWearable

Identifiers

PMID38753106
PMCPMC11213760

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.